{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T03:07:50Z","timestamp":1787368070690,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.leukres.2016.02.004","type":"journal-article","created":{"date-parts":[[2016,2,16]],"date-time":"2016-02-16T21:17:07Z","timestamp":1455657427000},"page":"39-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm"],"prefix":"10.1016","volume":"43","author":[{"given":"Jen Chin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Kundra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirela","family":"Andrei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Baptiste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Sindhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2016.02.004_bib0005","first-page":"100","article-title":"Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors","volume":"47","author":"Young","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2016.02.004_bib0010","first-page":"249","article-title":"Influence of mammary tumor progression on phenotype and function of spleen and in situ lymphocytes in mice","volume":"73","author":"Buessow","year":"1984","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.leukres.2016.02.004_bib0015","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.1073\/pnas.92.14.6254","article-title":"Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection","volume":"92","author":"Seung","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.leukres.2016.02.004_bib0020","doi-asserted-by":"crossref","first-page":"977","DOI":"10.4049\/jimmunol.179.2.977","article-title":"Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response","volume":"179","author":"Sinha","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2016.02.004_bib0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.semcancer.2005.07.005","article-title":"Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression","volume":"16","author":"Serafini","year":"2006","journal-title":"Semin. Cancer Biol."},{"issue":"7","key":"10.1016\/j.leukres.2016.02.004_bib0030","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.4049\/jimmunol.1203373","article-title":"Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow","volume":"190","author":"Ramachandran","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2016.02.004_bib0035","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.leukres.2016.02.004_bib0040","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1182\/blood-2007-07-099226","article-title":"Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T-cell suppressive activity","volume":"111","author":"Movahedi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.02.004_bib0045","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.4049\/jimmunol.181.8.5791","article-title":"Subsets of myeloid-derived suppressor cells in tumor-bearing mice","volume":"181","author":"Youn","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2016.02.004_bib0050","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.2006.08.5829","article-title":"Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine","volume":"25","author":"Filipazzi","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.02.004_bib0055","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1158\/0008-5472.CAN-09-3767","article-title":"Immature immunosuppressive CD14+HLA-DR-\/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign","volume":"70","author":"Poschke","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2016.02.004_bib0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.leukres.2016.02.004_bib0065","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.leukres.2016.02.004_bib0070","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(77)91539-2","article-title":"Immune complexes in myeloproliferative disorders","volume":"115","author":"Lewis","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2016.02.004_bib0075","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood.V58.5.904.904","article-title":"Immunologic abnormalities in myelofibrosis with activation of the complement system","volume":"58","author":"Gordon","year":"1981","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2016.02.004_bib0080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00000441-196908000-00004","article-title":"Coombs\u2019 positive hemolytic anemia in myelofibrosis with myeloid metaplasia","volume":"258","author":"Khumbanonda","year":"1969","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.leukres.2016.02.004_bib0085","first-page":"272","article-title":"Lupus anticoagulant in myelofibrosis","author":"Bernhardt","year":"1976","journal-title":"Am. J. Med. Sci."},{"issue":"March (10)","key":"10.1016\/j.leukres.2016.02.004_bib0090","doi-asserted-by":"crossref","first-page":"e0116723","DOI":"10.1371\/journal.pone.0116723","article-title":"Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2Ralpha","volume":"3","author":"Jen Wang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2016.02.004_bib0095","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1365-2141.1994.tb04744.x","article-title":"Plasma soluble interleukin-2 receptor in patients with primary myelofibrosis","volume":"86","author":"Wang","year":"1994","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.leukres.2016.02.004_bib0100","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.3109\/10428194.2013.764417","article-title":"Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis","volume":"54","author":"Skov","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2016.02.004_bib0105","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.02.004_bib0110","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"26","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.leukres.2016.02.004_bib0115","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.02.004_bib0120","article-title":"PhD PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a Phase 1b study","volume":"290","author":"Moskowitz","year":"2014","journal-title":"ASH Annu. Meet. Abstr."},{"key":"10.1016\/j.leukres.2016.02.004_bib0125","doi-asserted-by":"crossref","first-page":"721s","DOI":"10.1158\/1078-0432.CCR-06-2197","article-title":"Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma","volume":"13","author":"Ochoa","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2016.02.004_bib0130","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4049\/jimmunol.166.1.678","article-title":"Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer","volume":"166","author":"Almand","year":"2001","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.leukres.2016.02.004_bib0135","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.02.004_bib0140","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1189\/jlb.0912461","article-title":"Blood CD33(+)HLA-DR(?) myeloid-derived suppressor cells are increased with age and a history of cancer","volume":"93","author":"Chris Verschoor","year":"2013","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.leukres.2016.02.004_bib0145","doi-asserted-by":"crossref","first-page":"e55818","DOI":"10.1371\/journal.pone.0055818","article-title":"Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1\/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia","volume":"8","author":"Christiansson","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.leukres.2016.02.004_bib0150","doi-asserted-by":"crossref","first-page":"e57114","DOI":"10.1371\/journal.pone.0057114","article-title":"Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2016.02.004_bib0155","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4049\/jimmunol.147.1.22","article-title":"Characterization and regulation of RB6\u20138C5 antigen expression on murine bone marrow cells","volume":"147","author":"Hestdal","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2016.02.004_bib0160","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4049\/jimmunol.1202088","article-title":"Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8\/A9 proinflammatory proteins","volume":"190","author":"Wang","year":"2013","journal-title":"J. Immunol."},{"issue":"February (2)","key":"10.1016\/j.leukres.2016.02.004_bib0165","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/blood.V51.2.189.189","article-title":"Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis","volume":"51","author":"Jacobson","year":"1978","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.02.004_bib0170","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2141.1992.tb08898.x","article-title":"Cytogenetic Studies of bone marrow fibroblasts cultured from patients with primary myelofibrosis","volume":"80","author":"Wang","year":"1992","journal-title":"Br. J. Haematol."},{"issue":"February (2)","key":"10.1016\/j.leukres.2016.02.004_bib0175","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.leukres.2016.02.004_bib0180","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3324\/haematol.2010.031070","article-title":"Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin3","volume":"96","author":"Barbui","year":"2011","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.leukres.2016.02.004_bib0185","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.exphem.2012.05.011","article-title":"Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis","volume":"40","author":"Skov","year":"2012","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2016.02.004_bib0190","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1600-0609.2011.01618.x","article-title":"Whole- blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis","volume":"87","author":"Skov","year":"2011","journal-title":"Eur. J. Haematol."},{"issue":"11","key":"10.1016\/j.leukres.2016.02.004_bib0195","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.leukres.2012.07.009","article-title":"Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance","volume":"36","author":"Skov","year":"2012","journal-title":"Leuk. Res."},{"issue":"11","key":"10.1016\/j.leukres.2016.02.004_bib0200","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.exphem.2010.07.005","article-title":"Oxidative stress is increased in primary and post-polycythemia vera myelofibrosis","volume":"38","author":"Vener","year":"2010","journal-title":"Exp. Hematol."},{"issue":"November (11)","key":"10.1016\/j.leukres.2016.02.004_bib0205","doi-asserted-by":"crossref","first-page":"e112786","DOI":"10.1371\/journal.pone.0112786","article-title":"Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defense genes in myelofibrosis and related neoplasms Potential implications of downregulation of nrf2 for genomic instability and disease progression","volume":"9","author":"Hasselbalch","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2016.02.004_bib0210","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"issue":"June (6)","key":"10.1016\/j.leukres.2016.02.004_bib0215","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1084\/jem.20062602","article-title":"MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis","volume":"204","author":"Delano","year":"2007","journal-title":"J. Exp. Med."},{"issue":"March (3)","key":"10.1016\/j.leukres.2016.02.004_bib0220","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"August (8)","key":"10.1016\/j.leukres.2016.02.004_bib0225","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood-2014-12-618595","article-title":"Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells","volume":"126","author":"Lu","year":"2015","journal-title":"Blood"},{"issue":"June (11)","key":"10.1016\/j.leukres.2016.02.004_bib0230","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.4049\/jimmunol.1103553","article-title":"Tumor-expressed inducible nitric oxide. synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release","volume":"188","author":"Jayaraman","year":"2012","journal-title":"J. Immunol."},{"issue":"19","key":"10.1016\/j.leukres.2016.02.004_bib0235","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood-2014-04-570572","article-title":"JAK2V617F1 myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2","volume":"124","author":"Kagoya","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.02.004_bib0240","unstructured":"Guanfang Shi, Maryna Yarotska, Chen Hui, Cherif Abdelmalek, Ching Wong, Madhumati Kalaovar, VLadimir Gottlieb, Jen-Chin Wang, The TLR-2 signal pathway is enhanced in myeloproliferative neoplasm\u2014related to the increased inflammatory cytokine and pathogenesis? ASH annual meeting (2015)."},{"issue":"November (11)","key":"10.1016\/j.leukres.2016.02.004_bib0245","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/leu.2013.102","article-title":"A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression","volume":"27","author":"Marty","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2016.02.004_bib0250","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3389\/fonc.2014.00349","article-title":"Myeloid-derived suppressor cells as therapeutic target in hematological malignancies","volume":"4","author":"De Veirman","year":"2014","journal-title":"Front. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616300182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616300182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T22:15:13Z","timestamp":1692224113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616300182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":50,"alternative-id":["S0145212616300182"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.02.004","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}